| Jamie Spence, APRN - CNS | |
|
731 12th Ave Nw Ste 302, Ardmore, OK 73401-5765 | |
| (580) 220-6200 | |
| (580) 220-6258 |
| Full Name | Jamie Spence |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Adult Health |
| Location | 731 12th Ave Nw Ste 302, Ardmore, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861845190 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | 72205 (Oklahoma) | Primary |
| Entity Name | Mercy Clinic Oklahoma Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386874550 PECOS PAC ID: 1153468921 Enrollment ID: O20091027000755 |
News Archive
Physicians should ask patients to take home blood pressure readings in the morning as well as the evening before making therapeutic decisions, say researchers.
Generic anti-epilepsy drugs, pharmaceutical products similar to brand-name versions, save consumers billions of dollars each year, but some are different enough from branded formulations that they may not be effective, particularly if patients switch between two generic drugs, a new study by Johns Hopkins researchers suggests.
Large proportions of European coronary patients are not benefitting from cardiac rehabilitation services, according to results of the third EUROASPIRE survey published today in the European Journal of Preventive Cardiology.
DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.
› Verified 2 days ago
| Entity Name | Genesis Medical Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578174074 PECOS PAC ID: 9739508698 Enrollment ID: O20200928001333 |
News Archive
Physicians should ask patients to take home blood pressure readings in the morning as well as the evening before making therapeutic decisions, say researchers.
Generic anti-epilepsy drugs, pharmaceutical products similar to brand-name versions, save consumers billions of dollars each year, but some are different enough from branded formulations that they may not be effective, particularly if patients switch between two generic drugs, a new study by Johns Hopkins researchers suggests.
Large proportions of European coronary patients are not benefitting from cardiac rehabilitation services, according to results of the third EUROASPIRE survey published today in the European Journal of Preventive Cardiology.
DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jamie Spence, APRN - CNS 2002 12th Ave Nw Ste B, Ardmore, OK 73401-1206 Ph: (580) 223-5180 | Jamie Spence, APRN - CNS 731 12th Ave Nw Ste 302, Ardmore, OK 73401-5765 Ph: (580) 220-6200 |
News Archive
Physicians should ask patients to take home blood pressure readings in the morning as well as the evening before making therapeutic decisions, say researchers.
Generic anti-epilepsy drugs, pharmaceutical products similar to brand-name versions, save consumers billions of dollars each year, but some are different enough from branded formulations that they may not be effective, particularly if patients switch between two generic drugs, a new study by Johns Hopkins researchers suggests.
Large proportions of European coronary patients are not benefitting from cardiac rehabilitation services, according to results of the third EUROASPIRE survey published today in the European Journal of Preventive Cardiology.
DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.
› Verified 2 days ago
Tamara Rae Brunk, APRN-CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 1115 Walnut Dr, Ardmore, OK 73401 Phone: 580-223-7472 Fax: 580-223-6673 |